{\rtf1\ansi\deff0\deftab360

{\fonttbl
{\f0\fswiss\fcharset0 Arial}
{\f1\froman\fcharset0 Times New Roman}
{\f2\fswiss\fcharset0 Verdana}
{\f3\froman\fcharset2 Symbol}
}

{\colortbl;
\red0\green0\blue0;
}

{\info
{\author Biblio 7.x}{\operator }{\title Biblio RTF Export}}

\f1\fs24
\paperw11907\paperh16839
\pgncont\pgndec\pgnstarts1\pgnrestart
Athanasakis E, Melloni E, Rigolin GMatteo, Agnoletto C, Voltan R, Vozzi D, Piscianz E, Segat L, dal Monego S, Cuneo A, Secchiero P, Zauli G. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. Oncotarget 2014;5(24):12635-45.\par \par Tisato V, Toffoli B, Monasta L, Bernardi S, Candido R, Zauli G, Secchiero P. Patients affected by metabolic syndrome show decreased levels of circulating platelet derived growth factor (PDGF)-BB. Clin Nutr 2013;32(2):259-64.\par \par Gonelli A, Radillo O, Drioli S, Rimondi E, Secchiero P, Bonora GMaria. Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL. Invest New Drugs 2012;30(2):828-32.\par \par Bernardi S, Norcio A, Toffoli B, Zauli G, Secchiero P. Potential role of TRAIL in the management of autoimmune diabetes mellitus. Curr Pharm Des 2012;18(35):5759-65.\par \par }